Funding agencies: This study was supported by the Parkinson Disease Research, Education, and Clinical Center of the Portland VA Medical Center, the RJG Foundation, and the Oregon Clinical and Translational Research Institute (grant UL1 RR024140).
Article first published online: 16 APR 2012
Copyright © 2012 Movement Disorder Society
Volume 27, Issue 6, pages 750–753, May 2012
How to Cite
Brod, L. S., Aldred, J. L. and Nutt, J. G. (2012), Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease. Mov. Disord., 27: 750–753. doi: 10.1002/mds.24998
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 30 MAY 2012
- Article first published online: 16 APR 2012
- Manuscript Revised: 15 FEB 2012
- Manuscript Accepted: 14 JAN 2012
- Manuscript Received: 7 DEC 2011
This article has been cited by:
- You have free access to this content3
- 4Dopa-decarboxylase gene polymorphisms affect the motor response to l-dopa in Parkinson's disease, Parkinsonism & Related Disorders, 2014, 20, 2, 170, , , , , , , , , , , , , ,
- 5Anti-Parkinson's disease drugs and pharmacogenetic considerations, Expert Opinion on Drug Metabolism & Toxicology, 2013, 9, 7, 859, , , ,
- 6Mood Disorders in Youth, Child and Adolescent Psychiatric Clinics of North America, 2013, 22, 3, 403,